{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002333","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.835055+00:00","generated_at":"2026-05-18T09:09:22.051471+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion Therapeutics wins Nasdaq hearing to stay listed; transfer to Capital Market with equity conditions","bullets":["Nasdaq panel granted continued listing subject to achieving $2.5M shareholders' equity by Sept 19, 2025.","Shares and warrants transfer from Global Market to Nasdaq Capital Market effective July 8, 2025, under same symbols.","To cure potential bid price deficiency, company plans 1-for-15 reverse share split after shareholder meeting on July 14, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002333","json":"https://secwatch.observer/filing/0001178913-25-002333.json","markdown":"https://secwatch.observer/filing/0001178913-25-002333.md","text":"https://secwatch.observer/filing/0001178913-25-002333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/0001178913-25-002333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002333/zk2533425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:09:22.051471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}